1 This adds to our confidence that RNAi therapeutics have enormous potential in the cardiometabolic space. How do RNAi therapeutics work and how are they administered to patients? Five of the six ...

“It’s really what the world of pharma has wanted for decades.” To learn more about RNA interference and the pioneering work of Alnylam, please visit us here.

Proving that prokaryotes possess an adaptive 'immune' response that is analogous to eukaryotic RNAi will be a long process. This work gives us a tantalizing glimpse of what lies ahead.